Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Strategy analysis > KOL Insight

KOL Insight


loader
  • Sort by Name
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products ascending
  • Display 45 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page

  • Multiple Myeloma KOL Interview – US

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and critical unmet needs are also discussed. Key therapies highlighted include Darzalex, Venclexta, Xpovio, Ygalo, Blenrep, and BCMA-targeted CAR-T therapies.

    May 15, 2020
    Find out more

  • Multiple Sclerosis (MS) KOL Interview – UK, London

    $599.00

    In this interview, a UK-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

    March 2, 2020
    Find out more

  • Multiple Sclerosis (MS) KOL Interview – UK, Southwest

    $599.00

    In this interview, a UK-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

    March 2, 2020
    Find out more

  • Multiple Sclerosis (MS) KOL Interview – US, Midwest

    $599.00

    In this interview, a US-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

    March 2, 2020
    Find out more

  • Multiple Sclerosis KOL Insight Interview

    $599.00

    Multiple Sclerosis KOL Insight Interview

    October 28, 2014
    Find out more

  • NASH KOL Insight Interview #1

    $599.00

    The prevalence data would suggest that in the US population about 30% of our population has fatty liver or NAFLD and of those 25% may have NASH and of those patients with NASH 25% percent may have fibrosis and progress to cirrhosis. It’s almost a pyramid effect, there may be 80 million Americans walking around with NAFLD, but to climb up to the top of the pyramid and develop cirrhosis would be about 5% of that total population, but that’s still significant because that would mean that the prevalence of cirrhosis [due to NASH] will exceed that of hepatitis C-related cirrhosis ten-fold

    February 20, 2014
    Find out more

  • NASH KOL Insight Interview #2

    $599.00

    KOL Highlights Include: The prevalence of cirrhosis due to NASH will far exceed that of cirrhosis due to Hepatitis C. Decreases in NAS score due to liver fat changes are not predictive of beneficial outcomes. Increasing LDL in patients with fatty liver disease is a concern. Results seen in animal models of NAFLD/NASH translate to […]

    March 4, 2014
    Find out more

  • Neuromodulation KOL Interview

    $599.00

    Neuromodulation KOL Interview

     

    February 5, 2015
    Find out more

  • Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Northeast

    $599.00

    Key topics discussed in this specialist interview with a US-based key opinion leader (KOL) include the diagnostic landscape in NASH and future market trends, with a focus on GLP-1 agonists, FGF 19/21 analogs, and FXR agonists.

    August 28, 2020
    Find out more
  • Non-Alcoholic Steatohepatitis (NASH) Survey

    Non-Alcoholic Steatohepatitis (NASH) Survey

    $599.00

    Datamonitor conducted a 4-question survey of 42 United States and 40 European (based in France, Germany, Italy and United Kingdom) gastroenterologists to gauge their views on late-stage clinical candidates in non-alcoholic steatohepatitis (NASH), including Ocaliva (ICPT), elafibranor (GNFTF) and selonsertib (GILD), and their projected use of these drugs if FDA-approved.

    March 9, 2017
    Find out more

  • Non-Small Cell Lung Cancer (NSCLC) KOL Interview – UK

    $599.00

    This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for non-small cell lung cancer (NSCLC). Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include AMG 510, MRTX849, capmatinib, tepotinib, TAK-788, poziotinib, pralsetinib, and selpercatinib.

    March 23, 2020
    Find out more

  • Non-Small Cell Lung Cancer (NSCLC) KOL Interview – US, East Coast

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for non-small cell lung cancer (NSCLC). Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include AMG 510, MRTX849, capmatinib, tepotinib, TAK-788, poziotinib, pralsetinib, and selpercatinib.

    March 23, 2020
    Find out more
  • Non-Small Cell Lung Cancer KOL Interview

    Non-Small Cell Lung Cancer KOL Interview

    $599.00

    Biomedtracker interviewed a lung cancer specialist based in the US to determine his views on the non-small cell lung cancer treatment landscape, with a focus on PD-1 immunotherapies.

    December 16, 2016
    Find out more

  • Non-Small Cell Lung Cancer KOL Interview – NH, US

    $1,099.00

    Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views

    August 30, 2018
    Find out more
  • Opioids and Chronic Neuropathic Pain Management KOL Interview

    Opioids and Chronic Neuropathic Pain Management KOL Interview

    $599.00

    Biomedtracker interviewed a neurologist based in the United States who currently treats over 1000 patients with chronic neuropathic pain per year to determine his current treatment practices for indications including fibromyalgia and views on the use of opioids and abuse-deterrent opioids.

    March 9, 2017
    Find out more

  • Ovarian Cancer KOL Interview – UK

    $599.00

    A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for ovarian cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include veliparib, mirvetuximab soravtansine, Recentin, ofranergene obadenovec, dostarlimab, Tecentriq, Keytruda, Imfinzi, and Opdivo.

    April 2, 2020
    Find out more

  • Ovarian Cancer KOL Interview – US, East Coast

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for ovarian cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include veliparib, mirvetuximab soravtansine, Recentin, dostarlimab, Tecentriq, Keytruda, Imfinzi, and Opdivo.

    April 1, 2020
    Find out more

  • Ovarian Cancer Pulse Survey

    $599.00

    Diagnostics/diagnostic techniques discussed:

    etarfolatide/folic acid, BRCA mutation testing

    May 7, 2014
    Find out more

  • Palbociclib for Breast Cancer

    $89.00

    Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer

    February 1, 2014
    Find out more

  • Pediatric Acute Leukemias (AML/ALL) KOL Interview

    $599.00

    Highlights Current manufacturing turnaround times for CAR-T products (2-3 weeks) for ALL are not a major limitation for pediatric leukemia patients. CAR-T treatments may be more acutely toxic than transplant immediately after infusion, but patients may have fewer medium- and long-term complications. Agents that target the cell cycle (CDK inhibitors, Aurora kinase inhibitors) will likely […]

    April 1, 2015
    Find out more

  • Pediatric Epilepsy KOL Interview – US, West

    $599.00

    A US expert in pediatric epilepsy provides insight into the approach to treating different forms of epilepsy. The key opinion leader (KOL) dives into the late-phase pipeline for epilepsy, as well as sharing insight into Epidiolex.

    February 18, 2019
    Find out more

  • Pneumococcal Vaccines KOL Interview

    $599.00

    Datamonitor interviewed three infectious diseases specialists to determine the physicians’ views on marketed and pipeline pneumococcal vaccines. Two physicians were based in Chicago, IL and one in the UK. The three interviews were combined into a single report.

    August 27, 2016
    Find out more

  • Post-AAIC KOL Interview

    $599.00

    Crenezumab data was negative in a Phase II study in mild to moderate AD. The signal in not pre-specified isn’t convincing. These data likely will have ethical implications for the asymptomatic, genetic AD predisposition study in the Columbian trial.

    August 6, 2014
    Find out more

  • Post-AASLD US KOL Interview

    $599.00

    Over 95% SVR for easy-to-treat patients, and it’s one pill a day for 8-12 weeks for most. In that context, the only way you can improve up on that is to improve care for all populations, not just for easy-to-treat but the difficult-to-treat: decompensated cirrhotics, the post-transplant, and HIV co-infected patients.

    December 16, 2014
    Find out more

  • Post-ADPD Alzheimer’s Disease KOL Interview

    $599.00

    Key Highlights BIIB-037 Amyloid beta PET data show positive Abeta reduction; cognitive results are not interpretable with such small numbers. (BIIB) BIIB-037 Phase Ib result interpretation may be effected by the ApoE4 dropouts in the treatment arm. (BIIB) MK-8931 and BIIB-037 show sufficient target engagement, but there is no evidence to date that amyloid clearance […]

    April 8, 2015
    Find out more
  • huntingtons-disease

    Post-CHDI Huntington’s Disease KOL Interview

    $799.00

    Indications: Huntington’s Disease, Alzheimer’s Disease Physician Information Specialty: Neurology Location: London, United Kingdom

    March 16, 2015
    Find out more

  • Post-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Survey

    $599.00

    Biomedtracker conducted a 5-question survey of 51 United States and 47 European (from France, Germany, Italy, Spain and United Kingdom) neurologists who currently treat patients in all stages of Alzheimer’s disease and who followed data presented at Clinical Trials on Alzheimer’s Disease (CTAD) 2016 to gauge their views on the pipeline anti-amyloid beta monoclonal antibodies solanezumab (LLY) and aducanumab (BIIB) and projected use of these potentially disease-modifying drugs if FDA-approved.

    March 9, 2017
    Find out more

  • Post-EASL KOL Insight Interview

    $599.00

    The European Association for the Study of the Liver (EASL) held the 2014 International Liver Meeting in
    London from April 9-13. The main focus of this year’s meeting was the clinical use of currently approved and
    soon-to-be approved, direct-acting antivirals for Hepatitis C.

     

    May 6, 2014
    Find out more

  • Post-EASL KOL Interview

    $599.00

    Highlights KOL believes elsbasvir and grazoprevir data will lead to approval and look similar to available drugs on the market (MRK). Post-liver transplant data for sofosbuvir and simpeprevir was positive (GLD, JNJ). Three DAA combination of -5816,-9857, and sofosbuvir looked good, but most physicians are erring on the side of conservative 12- week treatment regimens […]

    May 29, 2015
    Find out more
  • Prostate Cancer KOL Interview – UK #1

    Prostate Cancer KOL Interview – UK #1

    $599.00

    A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, and Lutetium 177Lu-PSMA-617.

    February 9, 2022
    Find out more
  • Prostate Cancer KOL Interview – UK #2

    Prostate Cancer KOL Interview – UK #2

    $599.00

    A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, and Lutetium 177Lu-PSMA-617.

    February 9, 2022
    Find out more

  • Prostate Cancer KOL Interview – US

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Diagnostic testing and unmet needs are also discussed. Key pipeline assets highlighted include Keytruda, Tecentriq, ipatasertib, DCVAC/PCa, capivasertib, Lutetium 177Lu-PSMA-617, and Cabometyx.

    November 10, 2020
    Find out more
  • Prostate Cancer KOL Interview – US, Northeast #2

    Prostate Cancer KOL Interview – US, Northeast #1

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, and Lutetium 177Lu-PSMA-617.

    February 9, 2022
    Find out more
  • Prostate Cancer KOL Interview – US, Northeast #2

    Prostate Cancer KOL Interview – US, Northeast #2

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, Lutetium 177Lu-PSMA-617, and CAN-2409.

    February 9, 2022
    Find out more

  • Psychiatry KOL Insight Interview

    $599.00

    At SfN, they showed some interesting preclinical data on the affect on the 5-HT7 and how it works in some animal models of cognition…especially those injected with PCPA. And you know in depression, they also did what we call the chronic mild stress (CMS)

    January 24, 2014
    Find out more

  • Renal Cell Carcinoma KOL Interview – UK

    $599.00

    This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for renal cell carcinoma. Disease stratifications by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Opdivo, Cabometyx, Keytruda, Inlyta, Lenvima, and Tecentriq.

    May 13, 2020
    Find out more

  • Renal Cell Carcinoma KOL Interview – US, Southeast

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for renal cell carcinoma. Disease stratifications by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Opdivo, Cabometyx, Keytruda, Inlyta, Lenvima, and Tecentriq.

    May 13, 2020
    Find out more
  • Respiratory Syncytial Virus (RSV) Prevention KOL Interview – UK

    Respiratory Syncytial Virus (RSV) Prevention KOL Interview – UK

    $599.00

    This interview with a UK-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

    December 22, 2021
    Find out more
  • Respiratory Syncytial Virus (RSV) Prevention KOL Interview

    Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #1

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

    December 22, 2021
    Find out more
  • Atopic Dermatitis and Psoriasis KOL Interview – US, Southeast

    Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #1

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

    November 18, 2021
    Find out more
  • Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #2

    Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #2

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

    December 22, 2021
    Find out more

  • Retinal Disorders (AMD and DME) Pulse

    $599.00

    We performed a 5-question survey of 20 ophthalmologists who treat retinal diseases to gauge current usage and projected future usage of agents for the treatment of wet and dry age-related macular degeneration (AMD) and diabetic macular edema (DME).

    October 27, 2014
    Find out more

  • Rheumatoid Arthritis KOL Interview – California, US

    $599.00

    A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more

  • Rheumatoid Arthritis KOL Interview – New Jersey, US

    $599.00

    A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more

  • Rheumatoid Arthritis KOL Interview – New Jersey, US

    $599.00

    A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more
Page 4 of 5
Page 4 of 512345
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Datamonitor Healthcare is part of Pharma intelligence Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
  • Informa PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726
informa
Call Back
Scroll to top